Cybin Inc., a biotechnology company based in Ontario, Canada, has successfully completed an exempt offering of securities, raising a total of $108,699,999 USD as per the Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which was not subject to review by the SEC for accuracy, was conducted under Rule 506(b) of Regulation D, allowing the company to raise capital from accredited investors without the need for a full registration. The first sale date was reported as March 19, 2024, and the offering was completed without extending beyond a year. Cybin Inc. reported that none of the proceeds would be used for payments to its executive officers, directors, or promoters. The company's executive team, including Chief Financial Officer Greg Cavers, was listed in the filing. Haywood Securities Inc. and Haywood Securities (USA) Inc. were involved in the offering, with sales commissions totaling $6,072,000 USD. The company did not disclose its revenue range or aggregate net asset value, and the securities were offered exclusively as equity.

Cybin Inc., a biotechnology company based in Ontario, Canada, has successfully completed an exempt offering of securities, raising a total of $108,699,999 USD as per the Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which was not subject to review by the SEC for accuracy, was conducted under Rule 506(b) of Regulation D, allowing the company to raise capital from accredited investors without the need for a full registration. The first sale date was reported as March 19, 2024, and the offering was completed without extending beyond a year. Cybin Inc. reported that none of the proceeds would be used for payments to its executive officers, directors, or promoters. The company's executive team, including Chief Financial Officer Greg Cavers, was listed in the filing. Haywood Securities Inc. and Haywood Securities (USA) Inc. were involved in the offering, with sales commissions totaling $6,072,000 USD. The company did not disclose its revenue range or aggregate net asset value, and the securities were offered exclusively as equity.